Acts as a sub-contractor on civil construction projects in India, with revenue running through a single construction activity segment. Customers include larger EPC contractors such as KMC Constructions Limited and pharma-sector clients such as MSN Life Sciences and MSN Laboratories. The work involves structural works, retaining walls, bridges and flyovers on highways, railway track formation, and civil and fabrication works at pharma facilities. Net profit was Rs 0.7238 crore in FY26 with EBITDA margin of 3.193%. Materials consumed run at 108.2% of revenue, leaving very little to cover employee and other operating costs. The company carries accumulated losses of Rs 2,592.78 lakhs, leaving its net worth at negative Rs 2,092.75 lakhs, supported by long-term borrowings of Rs 2,071.95 lakhs. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Construction activity. Small sub-contracted civil construction with weak balance sheet and negative net worth
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 24 |
| EBITDA (ex other income) | (0) | (1) | (0) | (1) | 1 |
| margin % | — | (92142.9) | — | — | 3.2 |
| Owners' profit | (0) | (1) | (0) | 13 | 1 |
| EPS, as reported (₹) | (0.34) | (1.29) | (0.94) | 26.02 | 1.45 |
| ROE % · ROCE % | 0.5 · (11.5) | 1.9 · (85.6) | 0.7 · (33.1) | (60.1) · (3873.8) | (3.5) · 30.0 |
| Debt / equity (x) | (0.01) | 0.00 | 0.00 | (0.98) | (1.11) |
| Cash from operations | (0) | (0) | (0) | 14 | (1) |
| Capex | 0 | 0 | 0 | 0 | 0 |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1 | 4 | 6 | 13 |
| Profit before tax | (0) | (0) | 14 | (1) | 0 | 0 | 0 | 0 |
| Net profit | (0) | (0) | 14 | (1) | 0 | 0 | 0 | 0 |
| EPS (₹) | (0.12) | (0.13) | 28.44 | 2.18 | 0.11 | 0.38 | 0.04 | 1.03 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| BAJAJ FINANCE LIMITED | 6,43,552 | 31.7 | 5.50 | 11.6 | 16.5 | — | 25.2 | 70.7 |
| SHRIRAM FINANCE LIMITED | 2,42,019 | 18.1 | 3.67 | 6.7 | 15.2 | — | 22.5 | 74.7 |
| CHOLAMANDALAM IN & FIN CO | 1,57,446 | 27.2 | 5.17 | 6.9 | 17.2 | — | 26.5 | 71.2 |
| TATA CAPITAL LIMITED | 1,54,110 | 28.2 | 3.27 | 6.5 | 10.4 | — | — | 75.8 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Promoter buys 55,645 shares, holding rises to 60.76% | ownership changes | medium | — | — |
| 10 Sept 2026 · Promoter Rama Swamy Reddy buys 55,645 shares, stake rises to 60.76% | ownership changes | high | — | — |
| 9 Sept 2026 · 32nd Annual Report and AGM Notice for FY 2025-26 filed | compliance | minimal | — | — |
| 9 Sept 2026 · 32nd AGM on Sep 30, 2026; FY26 accounts and director re-appointment | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Board approves draft Board Report, 32nd AGM on September 30, 2026 | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Board meeting on Sep 7, 2026 to fix 32nd AGM date and appoint scrutinizer | board shareholder meetings | low | — | — |
| 22 Aug 2026 · Newspaper publication of Board Meeting Notice and Financial Results | compliance | minimal | — | — |
| 8 Aug 2026 · Board meeting on 14 Aug to consider Q1 FY27 results | results | low | — | — |
| 30 Jul 2026 · RTA compliance certificate submitted for Q1 FY27 under SEBI Regulation 74(5) | compliance | minimal | — | — |
| 25 Jul 2026 · New work order of about Rs. 5.9 Cr from MSN Life Sciences | business updates | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| MUTHOOT FINANCE LIMITED | 1,12,094 | 9.9 | 2.82 | 3.9 | 26.7 | — | 22.0 | 84.0 |
| SBI CARDS & PAY SER LTD | 62,349 | 27.4 | 3.96 | — | 13.8 | — | — | 33.1 |
| HDB FINANCIAL SERVICES L | 55,706 | 20.2 | 2.70 | — | 12.3 | — | — | 58.0 |
| SUNDARAM FINANCE LTD | 52,217 | 23.3 | 3.51 | 6.7 | 13.8 | — | — | 78.4 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 28.3 | 18.2 | 140 of 212 | 34% |
| ROCE | 30.0 | 2.1 | 5 of 63 | 94% |
| ROE | (3.5) | 3.0 | 234 of 266 | 12% |
| Debt / Equity | (1.1) | 0.0 | 1 of 266 | 100% |
| EBITDA margin | 2.6 | 48.6 | 186 of 249 | 25% |
| Profit growth | 130.8 | 7.8 | 56 of 251 | 78% |
| Market cap | 22 | 37 | 162 of 260 | 38% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
